<DOC>
	<DOCNO>NCT00789763</DOCNO>
	<brief_summary>Phase I : Safety profile determine maximum tolerate dose ( MTD ) / Recommended Dose ( DR ) Sorafenib combination Gemcitabine Radiotherapy Phase II : Activity profile evaluate Progression-free rate ( PFR ) 6 month , Response rate , Overall survival , Toxicity profile</brief_summary>
	<brief_title>Phase I-II Evaluate Efficacy/Safety Sorafenib+Gemcitabine+Radiotherapy Locally Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description>Safety profile determine maximum tolerate dose ( MTD ) / Recommended Dose ( DR ) Sorafenib combination Gemcitabine Radiotherapy Definition maximum tolerate dose ( MTD ) : The MTD define high dose level give 6 patient 1 patient experience DLT . Definition Recommended Dose ( DR ) : Is MTD Definition Dose-limiting toxicity ( DLT ) : DLT define follow occur period treatment regard related combination regimen . - Grade 4 thrombocytopenia persist great 4 day , bleed require platelet transfusion - Grade 4 neutropenia last 7 day - Febrile neutropenia ( ≥ 38.5oC ) absolute neutrophil count ≤ 1000/mm3 - Any grade 3 4 non-hematologic toxicity relate combination [ occur despite optimal supportive care , applicable ] except hyperglycemia , hypoglycemia , deep venous thrombosis , hyperbilirubinemia secondary stent malfunction . - Hypertension symptomatic manage maximal use three different class antihypertensive , episode malignancy hypertension ( Detailed Dose Modifications G-CSF use case febrile neutropenia outline full protocol version ) Phase II Primary objective : Activity profile evaluate Progression-free rate ( PFR ) 6 month Secondary objective : Response rate Overall survival Toxicity profile</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients histological cytological confirm locally advanced pancreatic adenocarcinoma pancreatic carcinoma metastatic pancreatic carcinoma phase I . 2 . Patients measurable ( accord RECIST ) disease . 3 . Male female patient &gt; = 18 year old 4 . ECOG 01 5 . Adequate bone marrow , liver , renal function : Absolute neutrophil count ( ANC ) &gt; = 1,500/mm3 Platelets &gt; = 100,000/µl Hemoglobin &gt; =9.0 g/dl Total bilirubin &lt; 1.5 x upper limit normal . ALT AST &lt; = 2.5 x upper limit normal ( &lt; = 5X upper limit normal patient liver involvement ) Serum creatinine &lt; = 1.5 time x upper limit normal . Patients creatinine clearance &gt; = 45mL/min PT ( prothrombin time ) INR ( international normalize ratio ) PTT ( partial thromboplastin time ) &lt; =1.5 x 6 . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least six month last administration sorafenib 7 . Signed informed consent prior study specific procedures 1 . Patients previous treatment pancreatic carcinoma 2 . PTV ( plan target volume ) &gt; 500 cm3 5 cm ( maximum diameter ) 3 . Patients know suspected allergy iodated contrast renal impairment prevents radiological test . 4 . Pregnant nursing patient . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment 5 . General medical psychological condition would preclude appropriate inform consent compliance protocol . 6 . Previous cancer distinct primary site histology NSCLC except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor ( Ta Tis ) cancer curatively treat &gt; 3 year prior study entry 7 . Concurrent treatment experimental drug ( within 30 day prior study entry ) . 8 . Concurrent treatment anticancer therapy . 9 . Therapeutic anticoagulation Vitamin K antagonists warfarin heparin heparinoids . Low dose warfarin permit INR &lt; 1.5 . Low dose aspirin permit . 10 . Patients medical condition could jeopardize safety participation study . 11 . Significant weight loss ( &gt; equal 10 % body weight precede 6 week ) 12 . Major surgery within 3 previous week , laparoscopic biopsy significant traumatic injury within 2 week prior first dose study drug . 13 . Known suspected allergy sorafenib agent give course trial . 14 . Patients evidence history bleed diathesis coagulopathy 15 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month 16 . Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management 17 . Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina newonset angina ( begin within last 3 month ) myocardial infarction within last 6 month 18 . Patients ChildPugh class C hepatic impairment 19 . Patients severe renal impairment ( calculated creatinine clearance &lt; 30 ml/min ) require dialysis 20 . Active clinically serious infection &gt; CTCAE Grade 2 21 . Serious , nonhealing wound , ulcer , bone fracture 22 . Patients concomitant ketoconazole , itraconazole , ritonavir , rifampicin St. John 's Wort ( Hypericum perforatum ) . 23 . Known brain metastasis . Patients neurological symptom undergo CT scan/MRI brain exclude brain metastasis 24 . Any instable condition may interfere patient participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>Pancreatic cancer locally advance</keyword>
</DOC>